This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

About

Efficacy

Safety & Tolerability

Real World Experience

Support & Resources

Information on how to access XELJANZ®▼ (tofacitinib citrate) prescribing information and adverse event reporting can be found at the bottom of the page.

XELJANZ in Action

An alternative MoA targeting the JAK pathway1–3

XELJANZ inhibits the effects of pro-inflammatory cytokines through intracellular targeting of the JAK pathway3

  • XELJANZ works inside the cell to inhibit inflammation by blocking JAK-dependent signalling pathways4​​​​​​​
  • This reduces the production of multiple pro-inflammatory cytokines4,5

JAK, Janus kinase; MOA, mode of action


Prescribing Information:
​​​​​​​

Xeljanz (tofacitinib citrate) Prescribing Information (Great Britain) - 5mg film-coated tablets
Xeljanz (tofacitinib citrate) Prescribing Information (Great Britain) - 10mg film-coated tablets
Xeljanz (tofacitinib citrate) Prescribing Information (Northern Ireland) -  5mg and 10mg film-coated tablets
​​​​​​​Xeljanz (tofacitinib citrate) Prescribing Information (Great Britain) -  11mg prolonged release tablets
Xeljanz (tofacitinib citrate) Prescribing Information (Northern Ireland) -  11mg prolonged release tablets


References:
  1. XELJANZ (tofacitinib citrate) Summary of Product Characteristics.
  2. Tanaka Y, Yamaoka K. Mod Rheumatol 2012; 23:415–424.
  3. Fleischmann R. Curr Opin Rheumatol 2012; 24:335–341.
  4. O’Shea JJ et al. Ann Rev Med 2015; 66:311–328.
  5. McInnes IB, Liew FY. Nat Clin Pract Rheumatol 2005; 1:31–39
PP-XEL-GBR-3126. August 2021

Announcement Title

XELJANZ Risk Minimisation Programme (RMP) materials, including a Patient Alert Card, Prescriber Checklists and a Prescriber Brochure are available from https://www.medicines.org.uk/emc/. Patients treated with XELJANZ should be given the Patient Alert Card.

How XELJANZ works

Register to receive tailored marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. October 2020

Sign up now

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No